

# ForPatients

by Roche

Age-Related Macular Degeneration

## A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02698566 GX30020

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.

**Genentech, Inc.**  
Sponsor

**Phase 3**  
Phase

---

**NCT02698566 GX30020**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---